[Form 4] 60 Degrees Pharmaceuticals, Inc. Warrant Insider Trading Activity

Rhea-AI Filing Summary

Kristen Landon, Chief Operating Officer and director of 60 Degrees Pharmaceuticals, Inc., reports acquiring 4,540 shares of the issuer's common stock on 01/17/2025. The reported acquisition was at no cash price ($0) and leaves Ms. Landon with 4,540 shares held directly. The filing notes it was submitted late due to an inadvertent administrative error and that the reported share totals were adjusted to reflect a 1-for-5 reverse stock split effective 02/24/2025. The Form 4 is signed by the reporting person on 08/14/2025. All information is limited to this single non-derivative purchase; no derivative transactions or prices other than $0 are reported.

Positive

• Transparency: Filing discloses the acquisition and explains the late submission as an inadvertent administrative error.
• Clarity on corporate action: The report explicitly notes adjustment of share counts for the 1-for-5 reverse stock split effective 02/24/2025.

Negative

• Late filing: The Form 4 was filed late, which is a compliance lapse requiring remediation.
• Limited materiality: The single reported acquisition (4,540 shares) is small in isolation and the filing provides no context on total outstanding shares or ownership percentage.

Insights

Securities Analyst

TL;DR: Officer purchased 4,540 shares at $0; filing late and totals adjusted for a 1-for-5 reverse split.

From a regulatory and disclosure perspective, this Form 4 documents a small non-derivative acquisition by an insider who is both an officer and director. The $0 reported price suggests the shares may have been issued as a grant or similar compensatory award rather than an open-market purchase; the filing does not specify the grant mechanism. The late filing is disclosed as inadvertent, which raises governance and compliance housekeeping considerations but is not by itself evidence of material misconduct. The reverse split adjustment clarifies post-split holdings, important for accurately assessing ownership percentages.

Corporate Governance Expert

TL;DR: Insider grant reported, administrative late filing noted; ownership impact appears immaterial in scale.

The document shows an insider received 4,540 shares recorded at $0 and held directly. The filing discloses a late submission attributed to an administrative error, which governance teams typically track to prevent recurrence. The reverse split note explains the adjusted share count; without total outstanding share data or percentage ownership, materiality to shareholders cannot be quantified from this filing alone. No derivative positions or dispositions are reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Landon Kristen

(Last) (First) (Middle)

C/O 60 DEGREES PHARMACEUTICALS, INC.

1025 CONNECTICUT AVENUE NW SUITE 1000

(Street)

WASHINGTON DC 20036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
60 DEGREES PHARMACEUTICALS, INC. [ SXTP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)(2)	01/17/2025		A		4,540	A	$0	4,540	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This Form 4 is being filed late due to an inadvertent administrative error.

2. The number of shares has been adjusted to reflect the 1-for-5 reverse stock split effected by the Issuer on February 24, 2025.

	/s/ Kristen Landon	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Kristen Landon report on the Form 4 for 60 Degrees Pharmaceuticals (SXTP)?

The Form 4 reports an acquisition of 4,540 shares of common stock on 01/17/2025, leaving 4,540 shares beneficially owned directly.

Was there a price paid for the shares reported on the Form 4?

The transaction is reported with a price of $0, indicating the shares were issued or granted rather than purchased for cash according to the filing.

Why were the reported share amounts adjusted in the Form 4?

The filing states share counts were adjusted to reflect a 1-for-5 reverse stock split effected on 02/24/2025.

Did the filing disclose any derivative transactions or dispositions?

No. The Form 4 contains only a non-derivative acquisition; no derivative transactions or dispositions are reported.

Was the Form 4 filed on time?

No. The filing states it was submitted late due to an inadvertent administrative error.